Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Studie av INCA036978 hos deltakere med myeloproliferative neoplasi

12. november 2026 oppdatert av: Incyte Corporation

En fase 1, åpen, multikenterstudie av INCA036978 hos deltakere med myeloproliferative neoplasi

This study will be conducted to determine the safety, tolerability, dose-limiting toxicity (DLT)s, and maximum tolerated dose (MTD) and/or recommended dose for expansion (RDE)s of INCA036978 administered as monotherapy and in combination with a standard disease-directed therapy.

Studieoversikt

Studietype

Intervensjonell

Registrering (Antatt)

218

Fase

  • Fase 1

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

  • Navn: Incyte Corporation Call Center (US)
  • Telefonnummer: 1.855.463.3463
  • E-post: medinfo@incyte.com

Studer Kontakt Backup

  • Navn: Incyte Corporation Call Center (ex-US)
  • Telefonnummer: +800 00027423
  • E-post: eumedinfo@incyte.com

Studiesteder

    • New South Wales
      • Concord, New South Wales, Australia, 02139
        • Rekruttering
        • Concord General Repatriation Hospital
      • St Leonards, New South Wales, Australia, 02065
        • Rekruttering
        • Royal North Shore Hospital
    • Queensland
      • Auchenflower, Queensland, Australia, 04066
        • Rekruttering
        • Icon Cancer Centre
    • Victoria
      • East Melbourne, Victoria, Australia, 03002
        • Rekruttering
        • Epworth Health Care
    • Western Australia
      • Nedlands, Western Australia, Australia, 06009
        • Rekruttering
        • Linear Clinical Research
      • Liège, Belgia, 04000
        • Har ikke rekruttert ennå
        • Centre Hospitalier Universitaire (Chu) de Liege
      • Roeselare, Belgia, 08800
        • Har ikke rekruttert ennå
        • AZ DELTA
    • Ontario
      • Toronto, Ontario, Canada, M5G 2M9
        • Rekruttering
        • Princess Margaret Cancer Centre
    • Quebec
      • Montreal, Quebec, Canada, H3T 1E2
        • Har ikke rekruttert ennå
        • McGill University Jewish General Hospital
    • Alabama
      • Birmingham, Alabama, Forente stater, 35233
        • Har ikke rekruttert ennå
        • University of Alabama At Birmingham
    • California
      • Irvine, California, Forente stater, 92618
        • Rekruttering
        • City of Hope-Lennar Foundation Cancer Center
      • Los Angeles, California, Forente stater, 90095
        • Har ikke rekruttert ennå
        • UCLA Medical Hematology & Oncology
      • Los Angeles, California, Forente stater, 90033
        • Har ikke rekruttert ennå
        • Usc Norris Comprehensive Cancer Center
    • Connecticut
      • New Haven, Connecticut, Forente stater, 06510
        • Har ikke rekruttert ennå
        • Yale Cancer Center
    • Florida
      • Miami, Florida, Forente stater, 33136
        • Har ikke rekruttert ennå
        • University of Miami
      • Tampa, Florida, Forente stater, 33612
        • Har ikke rekruttert ennå
        • Moffitt Cancer Center
    • Georgia
      • Atlanta, Georgia, Forente stater, 30322
        • Rekruttering
        • Winship Cancer Institute of Emory University
    • Maryland
      • Baltimore, Maryland, Forente stater, 21287
        • Har ikke rekruttert ennå
        • John Hopkins Hospital
    • Massachusetts
      • Boston, Massachusetts, Forente stater, 02114
        • Rekruttering
        • Massachusetts General Hospital
    • Missouri
      • St Louis, Missouri, Forente stater, 63108
        • Har ikke rekruttert ennå
        • Washington University School of Medicine
    • New York
      • New York, New York, Forente stater, 10065
        • Har ikke rekruttert ennå
        • Weill Cornell Medicine
      • New York, New York, Forente stater, 10029
        • Har ikke rekruttert ennå
        • Mount Sinai School of Medicine
      • New York, New York, Forente stater, 10021
        • Har ikke rekruttert ennå
        • Memorial Sloan Kettering Cancer Center
    • North Carolina
      • Chapel Hill, North Carolina, Forente stater, 27514
        • Rekruttering
        • University of North Carolina At Chapel Hill
      • Charlotte, North Carolina, Forente stater, 28204
        • Har ikke rekruttert ennå
        • Levine Cancer Institute
      • Durham, North Carolina, Forente stater, 27705
        • Har ikke rekruttert ennå
        • Duke University Medical Center, Department of Hematologic Malignancies and Cellular Therapy
    • Ohio
      • Cleveland, Ohio, Forente stater, 44195
        • Har ikke rekruttert ennå
        • Cleveland Clinic
      • Columbus, Ohio, Forente stater, 43210
        • Rekruttering
        • Ohio State University
    • Tennessee
      • Nashville, Tennessee, Forente stater, 37203
        • Rekruttering
        • Tristar Bmt/Tcto
    • Texas
      • Houston, Texas, Forente stater, 77030
        • Har ikke rekruttert ennå
        • University of Texas M. D. Anderson Cancer Center
    • Utah
      • Salt Lake City, Utah, Forente stater, 84112
        • Har ikke rekruttert ennå
        • Huntsman Cancer Institute
    • Wisconsin
      • Milwaukee, Wisconsin, Forente stater, 53226
        • Har ikke rekruttert ennå
        • Medical College of Wisconsin
      • Bordeaux, Frankrike, 33076
        • Rekruttering
        • Francois-Xavier
      • Paris, Frankrike, 75010
        • Rekruttering
        • Hospital Saint Louis
      • Villejuif, Frankrike, 94805
        • Rekruttering
        • Institut Gustave Roussy
      • Bologna, Italia, 40138
        • Har ikke rekruttert ennå
        • Aou Policlinico S. Orsola-Malpighi
      • Milan, Italia, 20122
        • Har ikke rekruttert ennå
        • Fondazione Irccs Ca' Granda - Ospedale Maggiore Policlinico
      • Roma, Italia, 00168
        • Har ikke rekruttert ennå
        • A. Gemelli University Hospital, Catholic University of the Sacred Heart
      • Udine, Italia, 33100
        • Har ikke rekruttert ennå
        • Azienda Sanitaria Universitaria Friuli Centrale Asu Fc
      • Kashiwa Chiba, Japan, 277-0882
        • Har ikke rekruttert ennå
        • National Cancer Center Hospital East
      • Toon, Ehime, Japan, 791-0204
        • Har ikke rekruttert ennå
        • Ehime University Hospital
      • Badalona, Spania, 08916
        • Har ikke rekruttert ennå
        • Hospital Universitari Germans Trias I Pujol
      • Las Palmas de Gran Canaria, Spania, 35010
        • Har ikke rekruttert ennå
        • Hospital Universitario de Gran Canaria Dr. Negrin
      • Madrid, Spania, 28041
        • Har ikke rekruttert ennå
        • Hospital Universitario 12 de Octubre
      • London, Storbritannia, SE1 9RT
        • Har ikke rekruttert ennå
        • Guy'S Hospital - Guy'S & St Thomas' Nhs Foundation Trust
      • Nottingham, Storbritannia, NG5 1PB
        • Har ikke rekruttert ennå
        • Nottingham University Hospitals
      • Oxford, Storbritannia, OX3 7LE
        • Rekruttering
        • University of Oxford
      • Jongno-gu, Seoul, Sør -Korea, 03080
        • Har ikke rekruttert ennå
        • Seoul National University Hospital
      • Seocho-gu, Seoul, Sør -Korea, 06591
        • Har ikke rekruttert ennå
        • The Catholic University of Korea Seoul St. Mary'S Hospital
      • Aachen, Tyskland, D-52074
        • Rekruttering
        • University Medical Center Rwth Aachen
      • Berlin, Tyskland, 10117
        • Rekruttering
        • Charite Universitaetsmedizin Berlin - Campus Charite Mitte
      • Freiburg im Breisgau, Tyskland, 79106
        • Rekruttering
        • Universitatklinikum Freiburg
      • Halle, Tyskland, 06120
        • Rekruttering
        • Universitatsklinikum Halle (Saale)
      • Mainz, Tyskland, 55131
        • Har ikke rekruttert ennå
        • Universitatsmedizin Der Johannes Gutenberg-Universitat Mainz Iii

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år og eldre (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

  • Life expectancy > 6 months.
  • Willingness to undergo a pretreatment and limited on-study BM biopsies and aspirates (as appropriate to disease).
  • Participants with MF, PV and ET as defined in the protocol.

Exclusion Criteria:

  • Presence of any hematological malignancy other than MF, PV, or ET.
  • Malignancy within the last 3 years prior to enrollment.
  • Acute or chronic HBV, Active HCV or known HIV or tuberculosis infection.
  • Clinically significant or uncontrolled cardiac disease.
  • Has undergone any prior allogeneic stem-cell transplantation or such transplantation is planned in the next 6 months.
  • Laboratory values outside the Protocol-defined ranges.
  • Prior history of major bleeding or thrombosis within the last 3 months prior to study enrollment.
  • Presence of chronic or current active infectious disease requiring systemic treatment.
  • Treatment with an MPN-directed therapy (approved or investigational) within the per protocol threshold before the administration of study drug.
  • Prior radiation therapy within 28 days before the first dose of study treatment.

Other protocol-defined Inclusion/Exclusion Criteria may apply.

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: Randomisert
  • Intervensjonsmodell: Sekvensiell tildeling
  • Masking: Ingen (Open Label)

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: Part 1a: Dose Escalation

INCA036978 will be administered at a protocol defined starting regimen as monotherapy to identify the MTD and/or RDE(s).

INCA036978 will be administered at protocol defined dose.

Eksperimentell: Part 1b: Dose Escalation

INCA036978 will be administered at a protocol defined starting regimen in combination with a standard disease-directed therapy to identify the MTD and/or RDE(s).

INCA036978 will be administered at protocol defined dose.

A standard disease-directed therapy will be administered according to Prescribing Information/SmPC.

Eksperimentell: Part 2a: Dose Expansion

INCA036978 will be administered as monotherapy at the RDE(s) identified during Part 1

INCA036978 will be administered at protocol defined dose.

Eksperimentell: Part 2b: Dose Expansion

INCA036978 will be administered in combination with a standard disease-directed therapy at the RDE(s) identified during Part 1.

INCA036978 will be administered at protocol defined dose.

A standard disease-directed therapy will be administered according to Prescribing Information/SmPC.

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Number of participants with Dose Limiting Toxicities (DLT)s in Part 1
Tidsramme: Up to 28 days

Dose-limiting toxicity will be defined as the occurrence of any of the toxicities as per protocol.

Up to 28 days
Number of participants with Treatment-emergent Adverse Events (TEAEs)
Tidsramme: Up to approximately 2 years

Defined as adverse events AE (either reported for the first time or the worsening of a pre-existing event) occurring after the first dose of study drug and up to 60 days after last dose of study drug or until the start of a new disease-directed therapy, whichever occurs first.

Up to approximately 2 years
Number of participants with TEAEs leading to dose modification or discontinuation
Tidsramme: Up to approximately 2 years

Number of participants with TEAEs leading to study drug modifications (interruptions, dose reduction) or discontinuation.

Up to approximately 2 years

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Pharmacokinetics Parameter: Cmax of INCA036978
Tidsramme: Up to approximately 2 years

Defined as maximum observed plasma concentration of INCA036978.

Up to approximately 2 years
Pharmacokinetics Parameter: Tmax of INCA036978
Tidsramme: Up to approximately 2 years

Defined as the time to reach the maximum plasma concentration of INCA036978.

Up to approximately 2 years
Pharmacokinetics Parameter: Cmax,ss of INCA036978
Tidsramme: Up to approximately 2 years

Defined as the maximum observed plasma concentration at steady state of INCA036978.

Up to approximately 2 years
Pharmacokinetics Parameter: Cmin,ss of INCA036978
Tidsramme: Up to approximately 2 years

Defined as the minimum observed plasma concentration at steady state of INCA036978.

Up to approximately 2 years
Pharmacokinetics Parameter: AUC(0-t) of INCA036978
Tidsramme: Up to approximately 2 years

Defined as the area under the concentration-time curve up to the last measurable concentration of INCA036978.

Up to approximately 2 years
Pharmacokinetics Parameter: AUC 0-∞ of INCA036978
Tidsramme: Up to approximately 2 years

Defined as the area under the concentration-time curve from 0 to infinity of INCA036978.

Up to approximately 2 years
Pharmacokinetics Parameter: CL/F of INCA036978
Tidsramme: Up to approximately 2 years

Defined as the apparent clearance of INCA036978.

Up to approximately 2 years
Pharmacokinetics Parameter: Vz/F of INCA036978
Tidsramme: Up to approximately 2 years

Defined as the apparent volume of distribution of INCA036978.

Up to approximately 2 years
Pharmacokinetics Parameter: t1/2 of INCA036978
Tidsramme: Up to approximately 2 years

Defined as the apparent terminal phase disposition half-life of INCA036978.

Up to approximately 2 years
For participants with myelofibrosis (MF): Percentage of participants achieving spleen volume reduction as defined in the protocol
Tidsramme: Week 12 and Week 24

Defined as percentage of participants with a protocol defined spleen volume reduction.

Week 12 and Week 24
For participants with MF and anemia: Anemia Response as defined in the protocol
Tidsramme: Up to approximately 2 years

For non transfusion-dependent (TD) participants: An Hb increase relative to baseline as defined in the protocol if non-TD at baseline. For TD participants: Achieving transfusion independency (TI) as defined in the protocol.

Up to approximately 2 years
For participants with polycythemia vera (PV): Peripheral blood count remission as defined by the protocol.
Tidsramme: Up to approximately 2 years

Peripheral blood count remission as defined by the protocol.

Up to approximately 2 years
For participants with essential thrombocythemia (ET): Peripheral blood count remission as defined by the protocol.
Tidsramme: Up to approximately 2 years

Peripheral blood count remission as defined by the protocol.

Up to approximately 2 years

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Etterforskere

  • Studieleder: Incyte Medical Monitor, Incyte Corporation

Publikasjoner og nyttige lenker

Den som er ansvarlig for å legge inn informasjon om studien leverer frivillig disse publikasjonene. Disse kan handle om alt relatert til studiet.

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

11. mai 2026

Primær fullføring (Antatt)

24. mai 2030

Studiet fullført (Antatt)

24. mai 2030

Datoer for studieregistrering

Først innsendt

13. februar 2026

Først innsendt som oppfylte QC-kriteriene

26. februar 2026

Først lagt ut (Faktiske)

2. mars 2026

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

13. november 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

12. november 2026

Sist bekreftet

1. november 2026

Mer informasjon

Begreper knyttet til denne studien

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

NEI

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Ja

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere